Physicians' Academy for Cardiovascular Education

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure

10' education - June 21, 2022 - Prof. Andrew Coats, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

The future of heart failure management: rethinking approaches to care

10' education - June 21, 2022 - Ileana L. Piña, MD, Javed Butler, MD, Marco Metra, MD, and Giuseppe M.C. Rosano, MD, PhD

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

Findings of analysis on pediatric FH patients in large global registry

3' education - June 16, 2022 - Kanika Dharmayat

Clinical implications of ESC/HFA guideline updates for iron deficiency in heart failure

10' education - June 13, 2022 - Javed Butler, MD and Piotr Ponikowski, MD, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 13, 2022 - Prof. Richard Hobbs, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD

Optimizing RAASi therapy in patients with HF and multiple comorbidities

10' education - May 31, 2022 - Gregg Fonarow, MD and Andrew Coats, MD

Wake-up call to shift focus from treating CVD to preserving CV health

3' education - May 31, 2022 - Prof. Lale Tokgözoğlu, MD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins

3' education - May 24, 2022 - Nicholas Marston, MD

What is the role of imaging and how can it guide medical therapy in ASCVD?

3' education - May 24, 2022 - Prof. Stephen Nicholls, MD

Welcome to the EAS 2022 congress

3' education - May 24, 2022 - Prof. Kausik Ray, MD

New oral therapy of CETP inhibition for lipid lowering

3' education - May 24, 2022 - Prof. Kausik Ray, MD

DOAC monotherapy reduces total adverse events in AF and stable coronary artery disease

Literature - June 27, 2022 - Naito R, et al. - JAMA Cardiol. 2022

In a post-hoc analysis of the AFIRE trial, rivaroxaban monotherapy was associated with a 38% lower risk of first and subsequent thrombotic and bleeding events in patients with AF and stable coronary artery disease compared with combination therapy of rivaroxaban with antiplatelet agents.

Thromboembolic complications common in ATTR-CM

Literature - June 27, 2022 - Vilches S, et al. - Eur J Heart Fail. 2022

ATTR-CM is a progressive, often fatal form of cardiac disease characterized by accumulation of transthyretin in the heart. It is unclear how often thromboembolic complications occur in patients with ATTR-CM.

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD
Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What is the best way to adress the CV risk in this patient?

Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?

20-year prognosis of hypertrophic cardiomyopathy: low mortality but high morbidity

Literature - June 21, 2022 - Sugiura K, et al. - ESC Heart Fail. 2022

In a community-based cohort study on hypertrophic cardiomyopathy (HCM), few patients died each year of the disease but HCM-related morbidity was substantial.

Updates to the Standards of Medical Care in Diabetes 2022 by ADA

News - June 21, 2022

The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.

Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure

10' education - June 21, 2022 - Prof. Andrew Coats, MD
Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.

Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD
Prof. McMurray talks about barriers and concerns regarding Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

The future of heart failure management: rethinking approaches to care

10' education - June 21, 2022 - Ileana L. Piña, MD, Javed Butler, MD, Marco Metra, MD, and Giuseppe M.C. Rosano, MD, PhD
Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.

Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.

SGLT2i reduces incidence of hyperkalemia in HF patients

Literature - June 21, 2022 - Ferreira JP, et al. - Eur Heart J. 2022

Hyperkalemia frequently leads to the interruption or discontinuation of treatment with RAAS inhibitors, which may worsen the prognosis of patients with HF. The SGLT2 inhibitor empagliflozin may offer relief here.

New brain infarcts in AF patients, despite anticoagulation, affect cognitive function

Literature - June 20, 2022 - Kühne M, et al. - Eur Heart J. 2022

In a large cohort of AF patients, new brain infarcts occurred frequently, despite a high anticoagulation rate. Both clinically overt and silent brain infarcts were associated with cognitive decline.

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

EAS 2022 "According to [these] data, there is no reason why you should give aspirin to an individual with high Lp(a)," says prof. Catapano. He recapitulates the findings of a study by Olmastroni and colleagues.

Findings of analysis on pediatric FH patients in large global registry

3' education - June 16, 2022 - Kanika Dharmayat
Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.

EAS 2022 Kanika Dharmayat talks about how to achieve early identification of FH patients based on findings from an analysis of the EAS FHSC global registry on children and adolescents with FH.

Agenda